Tetraphase Pharmaceuticals Overview

  • Founded
  • 2006
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 67
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $59M
Latest Deal Amount

Tetraphase Pharmaceuticals General Information

Description

Tetraphase Pharmaceuticals Inc is a biopharmaceutical company using its proprietary chemistry technology to create, develop and commercialize novel tetracyclines for serious and life-threatening conditions, including bacterial infections caused by multidrug-resistant, or MDR, bacteria. The company has developed its product, Xerava (eravacycline), a fully synthetic fluorocycline, as an intravenous, or IV antibiotic for use as a first-line empiric monotherapy for the treatment of MDR infections, including MDR Gram-negative infections, such as those found in complicated intra-abdominal infections, or cIAI.

Contact Information

Website
www.tphase.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Parent Company
La Jolla Pharmaceutical
Primary Office
  • 480 Arsenal Way
  • Suite 100
  • Watertown, MA 02472
  • United States
+1 (617) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Tetraphase Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Merger/Acquisition 28-Jul-2020 $59M 00000 0000 Completed Generating Revenue/Not Profitable
10. Merger/Acquisition 16-Mar-2020 000.00 000.00 Cancelled Generating Revenue/Not Profitable
9. PIPE 22-Jan-2020 000.00 00000 Completed Generating Revenue
8. Secondary Transaction - Open Market 01-Mar-2018 00000 Completed Generating Revenue
7. 2PO 27-Jul-2017 0000 00000 Completed Generating Revenue
6. 2PO 11-Mar-2015 00000 00000 00.000 Completed Generating Revenue
5. Secondary Transaction - Open Market 01-Mar-2015 00000 Completed Generating Revenue
4. IPO 20-Mar-2013 0000 00000 00000 Completed Generating Revenue
3. Later Stage VC (Series C) 01-Jun-2010 $45.1M $70.1M 00000 Completed Generating Revenue
2. Early Stage VC (Series B) 06-Oct-2009 $10.1M $25M 000.00 Completed Startup
To view Tetraphase Pharmaceuticals’s complete valuation and funding history, request access »

Tetraphase Pharmaceuticals Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series C 000,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series B 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A2 13,095,646 $0.001000 $0.69 $0.69 1x $0.18 16.31%
Series A1 10,072,000 $0.001000 $0.6 $0.6 1x $0.18 10.9%
To view Tetraphase Pharmaceuticals’s complete cap table history, request access »

Tetraphase Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Tetraphase Pharmaceuticals Inc is a biopharmaceutical company using its proprietary chemistry technology to create, deve
Pharmaceuticals
Watertown, MA
67 As of 2019
00000
000 0000-00-00
000000&0 00000

00000000

velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident,
0000 000000000
Jersey City, NJ
00 As of 0000
00000
000000000 00000

0000000

eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud ex
000000000000000
Waltham, MA
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Tetraphase Pharmaceuticals Competitors (22)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Scynexis Formerly VC-backed Jersey City, NJ 00 00000 000000000 00000
0000000 0000000000 Formerly VC-backed Waltham, MA 00 00000 000000000 00000
0000000 0000000000 Formerly VC-backed Cambridge, MA 0000 00.00 00000000000 00.00
000000000 00000000 Formerly VC-backed Boston, MA 00 00000 000000000 00000
000000000 Venture Capital-Backed Basel, Switzerland 00 000.00 00000000000 000.00
You’re viewing 5 of 22 competitors. Get the full list »

Tetraphase Pharmaceuticals Executive Team (13)

Name Title Board Seat Contact Info
Christopher Watt Senior Vice President, Finance
Maria Stahl Chief Business Officer
Erik Phillips Finance Manager
Xiao-Yi Xiao Ph.D Vice President, Medicinal Chemistry
You’re viewing 4 of 13 executive team members. Get the full list »

Tetraphase Pharmaceuticals Board Members (13)

Name Representing Role Since
John Freund MD Self Board Member 000 0000
Patrick Gage Ph.D Self Chairman of the Board of Director 000 0000
You’re viewing 2 of 13 board members. Get the full list »

Tetraphase Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Tetraphase Pharmaceuticals Former Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Armistice Capital Hedge Fund Minority 000 0000 000000 0
BB Biotech Asset Manager Minority 000 0000 000000 0
Bay City Capital Venture Capital Minority 000 0000 000000 0
Excel Venture Management Venture Capital Minority 000 0000 000000 0
F-Prime Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »

Ready to get started?

Request a free trial